As previously mentioned, the index obtained by dividing the square of the CD62Llow CD4+ T cell ratio by the CD4+CD25+FOXP3+ T cell ratio, analyzed using pretreatment peripheral blood, can be used to predict the response to nivolumab therapy in patients with previously treated NSCLC [15]. This evidence concerns the gene CD4 and non-small cell lung carcinoma.